Kisspeptin-10 vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10GLP-1 / Weight Loss Agonists
Survodutide- Summary
- Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- ~7 days
- Admin Route
- SubQ, IV
- SubQ
- Research
- —
- —
- Typical Dose
- 50–500 mcg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once daily to every other day
- Once weekly
- Key Benefits
- Potently stimulates LH and testosterone
- Enhances sexual arousal and libido
- Activates HPG axis — upstream of GnRH
- May improve fertility in hypogonadotropic hypogonadism
- Increases brain activation in sexual attraction circuits
- May restore LH pulsatility in suppressed HPG axis
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Injection site reactions
- Temporary nausea
- Flushing
- Elevated LH/testosterone (intended effect)
- +1 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —